Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst'
March 30, 2017 at 08:46 AM EDT
On March 28, Galectin Therapeutics Inc (NASDAQ: GALT) provided an update on the progress of its lead program, the Phase 2b trial of ...
